New Horizon Research Center (NHRC) is a multi-specialty research facility conveniently located in Kendall Regional Medical Plaza just 12 miles from Miami International Airport. NHRC has successfully conducted Phase I through IV research studies.
Our Mission is excellence in conducting research, to assist the healthcare industry in developing new therapies that will bring hope to our patients.
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS XXXX in Adult Patients with Type 2 Diabetes Mellitus: the ELEMENT 5 Study.
The ABER clinical research study will look at the safety and effectiveness of an investigational study drug compared to an approved comparator in individuals with type 2 diabetes mellitus.
A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
The FREEDOM program consists of a group of Phase 3 clinical research studies evaluating an investigational product (ITCA 650) for patients with type 2 diabetes (T2DM). ITCA 650 is an osmotic mini-pump that can deliver a continuous and consistent infusion of exenatide for up to 12 months from a single subcutaneous placement.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients with Chronic Idiopathic Constipation
The Pretreatment Period is defined as the 14 to 21 calendar days immediately before the Randomization Visit. During this period, patients will provide the following information through daily calls to an interactive voice response system (IVRS):
- Daily Bowel Habits and Daily Patient Symptom Severity Assessments - Weekly Patient Assessments - Weekly Patient Assessment of Constipation Severity
- Weekly Patient Assessment of Degree of Relief of Constipat ion Symptoms
- Use of Per-protocol Rescue Medicine or Any Other Laxatives, Suppositories, or Enemas
Patients who satisfy all of the entry criteria will enter the treatment Period.
Treatment Period: The Treatment Period begins with randomization and lasts for 12 weeks. Patients will be tratified by baseline SBM frequency (i.e., those with > 1SBM/week and those with ≤ 1 SBM/week) and will be randomized to treatment.
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza
Subjects will be enrolled within 48 hours of onset of influenza clinical symptoms (symptoms must start 48 hours or less prior to the first dose of study medication).
